Insider Transactions Reported by 13 Insiders of Larimar Therapeutics, Inc.

Symbol
LRMR on Nasdaq
Location
Bala Cynwyd, PA

Insiders trading volume in the past year

Larimar Therapeutics, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
James E. Flynn Director, * Director by Deputization, 10%+ Owner $178,034,870 +$55,000,000 +45% 27 Feb 2026
DEERFIELD PARTNERS, L.P. Director, Dir. by Deputization/10% Group, 10%+ Owner $10,367,497 16 Sep 2022
Thomas Edward Hamilton Director $3,910,703 +$500,000 +15% 27 Feb 2026
Carole Ben-Maimon President and CEO, Director $1,521,835 26 Jan 2026
Michael Celano Chief Financial Officer $822,140 26 Jan 2026
Gopi Shankar Chief Development Officer $291,247 26 Jan 2026
Russell Clayton Chief Medical Officer $272,197 26 Jan 2026
Frank E. Thomas Director $35,000 +$25,000 +250% 27 Feb 2026
Jeffrey W. Sherman Director $25,000 +$25,000 27 Feb 2026
Peter Barrett Director 10 May 2022
Joseph Truitt Director 13 May 2025
Jonathan S. Leff Director 13 May 2025
Daniel Thomas O Director 12 May 2021

Recent Insider Transactions by Companies or Individuals for Larimar Therapeutics, Inc.

Showing up to 300 most recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
James E. Flynn LRMR Common Stock Purchase 47.5% $10,000,000 $5.00 2,000,000 6,207,982 27 Feb 2026 Through Deerfield Partners, L.P.
James E. Flynn LRMR Common Stock Purchase 11.4% $4,159,890 $5.00 831,978 8,153,107 27 Feb 2026 Through Deerfield Healthcare Innovations Fund, L.P.
James E. Flynn LRMR Common Stock Purchase 11.4% $5,420,060 $5.00 1,084,012 10,622,957 27 Feb 2026 Through Deerfield Private Design Fund IV, L.P.
James E. Flynn LRMR Common Stock Purchase 11.4% $5,420,050 $5.00 1,084,010 10,622,928 27 Feb 2026 Through Deerfield Private Design Fund III, L.P.
Thomas Edward Hamilton LRMR Common Stock Purchase 17.7% $500,000 $5.00 100,000 664,798 27 Feb 2026 Direct
Frank E. Thomas LRMR Common Stock Purchase 250% $25,000 $5.00 5,000 7,000 27 Feb 2026 Direct
Jeffrey W. Sherman LRMR Common Stock Purchase $25,000 $5.00 5,000 5,000 27 Feb 2026 Direct
Gopi Shankar LRMR Common Stock Award 50.5% 25,637 76,443 26 Jan 2026 Direct
Gopi Shankar LRMR Stock Option (Right to Buy) Award 153,822 153,822 26 Jan 2026 Direct
Russell Clayton LRMR Common Stock Award 56% 25,637 71,443 26 Jan 2026 Direct
Russell Clayton LRMR Stock Option (Right to Buy) Award 153,822 153,822 26 Jan 2026 Direct
Carole Ben-Maimon LRMR Common Stock Award 37.3% 100,100 368,276 26 Jan 2026 Direct
Carole Ben-Maimon LRMR Stock Option (Right to Buy) Award 600,600 600,600 26 Jan 2026 Direct
Michael Celano LRMR Common Stock Award 21.1% 37,604 215,785 26 Jan 2026 Direct
Michael Celano LRMR Stock Option (Right to Buy) Award 225,622 225,622 26 Jan 2026 Direct
James E. Flynn LRMR Common Stock Purchase 55.1% $8,319,782 $3.20 2,599,932 7,321,129 31 Jul 2025 Through Deerfield Healthcare Innovations Fund, L.P.
James E. Flynn LRMR Common Stock Purchase 55.1% $10,840,125 $3.20 3,387,539 9,538,945 31 Jul 2025 Through Deerfield Private Design Fund IV, L.P.
James E. Flynn LRMR Common Stock Purchase 55.1% $10,840,093 $3.20 3,387,529 9,538,918 31 Jul 2025 Through Deerfield Private Design Fund III, L.P.
James E. Flynn LRMR Stock Option (Right to Buy) Award 19,000 19,000 13 May 2025 Through Deerfield Management Company, L.P.
Jeffrey W. Sherman LRMR Stock Option (Right to Buy) Award 19,000 19,000 13 May 2025 Direct
Joseph Truitt LRMR Stock Option (Right to Buy) Award 19,000 19,000 13 May 2025 Direct
Thomas Edward Hamilton LRMR Stock Option (Right to Buy) Award 19,000 19,000 13 May 2025 Direct
Frank E. Thomas LRMR Stock Option (Right to Buy) Award 19,000 19,000 13 May 2025 Direct
Jonathan S. Leff LRMR Stock Option (Right to Buy) Award 19,000 19,000 13 May 2025 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.